NCT06506955 2026-04-03
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
Clinical Trials
9 trialsNCT06474091 2026-03-16
Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)
Mayo Clinic
Enrolling by invitation
NCT05404503 2026-01-06
QuiCo
MarÃa Teresa Moreno Asencio
Enrolling by invitation
NCT06997913 2025-05-31
AICRC
The First Affiliated Hospital of Air Force Medicial University
Enrolling by invitation
NCT06963060 2025-05-08
GALENT-BT
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Enrolling by invitation
NCT06901622 2025-03-30
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Enrolling by invitation
NCT01868490 2025-02-10
The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells
Siriraj Hospital
Phase 1/2 Enrolling by invitation
NCT04572711 2024-12-11
Prospective Evaluation of Biliary Tissue Sampling with ERCP
Mayo Clinic
Enrolling by invitation
NCT04195503 2024-10-10
Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma
University Health Network, Toronto
Phase NA Enrolling by invitation